Clover Health Investments (NASDAQ:CLOV – Get Free Report) and 111 (NASDAQ:YI – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Valuation and Earnings
This table compares Clover Health Investments and 111″s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clover Health Investments | $1.92 billion | 1.31 | -$85.55 million | ($0.12) | -40.00 |
| 111 | $1.80 billion | 0.02 | -$9.65 million | ($1.40) | -3.15 |
Institutional & Insider Ownership
19.8% of Clover Health Investments shares are held by institutional investors. Comparatively, 21.3% of 111 shares are held by institutional investors. 23.5% of Clover Health Investments shares are held by company insiders. Comparatively, 43.9% of 111 shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Clover Health Investments and 111’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clover Health Investments | -2.58% | -16.52% | -9.28% |
| 111 | -0.76% | N/A | -3.80% |
Risk and Volatility
Clover Health Investments has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for Clover Health Investments and 111, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clover Health Investments | 1 | 3 | 1 | 0 | 2.00 |
| 111 | 1 | 0 | 0 | 0 | 1.00 |
Clover Health Investments presently has a consensus target price of $3.82, indicating a potential downside of 20.49%. Given Clover Health Investments’ stronger consensus rating and higher probable upside, research analysts plainly believe Clover Health Investments is more favorable than 111.
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
About 111
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.
